1. Home
  2. VALU vs AKBA Comparison

VALU vs AKBA Comparison

Compare VALU & AKBA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Value Line Inc.

VALU

Value Line Inc.

HOLD

Current Price

$35.92

Market Cap

353.1M

Sector

Finance

ML Signal

HOLD

Logo Akebia Therapeutics Inc.

AKBA

Akebia Therapeutics Inc.

HOLD

Current Price

$1.39

Market Cap

380.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
VALU
AKBA
Founded
1931
2007
Country
United States
United States
Employees
N/A
N/A
Industry
Investment Managers
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
353.1M
380.4M
IPO Year
1995
2014

Fundamental Metrics

Financial Performance
Metric
VALU
AKBA
Price
$35.92
$1.39
Analyst Decision
Strong Buy
Analyst Count
0
6
Target Price
N/A
$5.75
AVG Volume (30 Days)
959.0
2.6M
Earning Date
03-16-2026
05-07-2026
Dividend Yield
3.61%
N/A
EPS Growth
8.91
93.94
EPS
1.92
N/A
Revenue
$36,257,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$18.74
N/A
Revenue Growth
1.08
N/A
52 Week Low
$35.15
$1.14
52 Week High
$41.85
$4.08

Technical Indicators

Market Signals
Indicator
VALU
AKBA
Relative Strength Index (RSI) 44.39 51.53
Support Level $35.15 $1.30
Resistance Level $38.09 $1.55
Average True Range (ATR) 0.47 0.07
MACD -0.02 0.00
Stochastic Oscillator 37.22 34.62

Price Performance

Historical Comparison
VALU
AKBA

About VALU Value Line Inc.

Value Line Inc is a U.S based company. It produces investment periodicals based on underlying research and making available copyright data, including ranking system and other information, to third parties under written agreements for use in third-party managed and marketed investment products and for other purposes. The company markets under brands including Value Line, the Value Line logo, The Value Line Investment Survey, Smart Research, Smarter Investing and a trusted name in Investment Research. Its only operating segment being Publishing.

About AKBA Akebia Therapeutics Inc.

Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics. The current portfolio of the company includes Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease, Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor approved in Japan for the treatment of anemia due to chronic kidney disease, and HIF-PH inhibitors in preclinical development.

Share on Social Networks: